Acute myeloid leukemia with translocation (1;21)
- 21 Downloads
Advancement in genetic and molecular biology techniques has greatly helped our understanding of various diseases, especially hematological disorders. We describe a case of primary myelofibrosis (PMF) that transformed into acute myeloid leukemia with a very rare and unusual genetic translocation of (1;21). There are only five reported cases of this translocation in acute myeloid leukemia (AML) or myelodysplastic syndrome but none of them transformed from PMF. This case not only highlights the importance of rare genetic translocations but also provides the natural history of the disease and its poor prognosis. To the best of our knowledge our patient is the first reported case of AML transformed from PMF to have this unique translocation of (1;21).
KeywordsAcute myeloid leukemia Primary myelofibrosis Translocation (1;21) AML transformation
All authors have contributed significantly, and are in agreement with the content of the manuscript.
Compliance with ethical standards
Conflict of interest
All authors have no conflict of interest.
Formal consent was obtained from the Hospital ethical committee and the manuscript is in accordance with the recommendations of Institutional Review Board of St. John, Hospital and Medical Center, Detroit, MI, USA. The manuscript complies with institutional, national, and international guidelines for using human subject/tissue.
- 7.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, LyonGoogle Scholar
- 10.Shiba N, Ichikawa H, Taki T, Park MJ, Jo A, Mitani S, Kobayashi T, Shimada A, Sotomatsu M, Arakawa H, Adachi S, Tawa A, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y (2013) NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia. Genes Chromosom Cancer 52(7):683–693. https://doi.org/10.1002/gcc.22064 PubMedGoogle Scholar
- 11.de Rooij JD, Hollink IH, Arentsen-Peters ST, van Galen JF, Berna Beverloo H, Baruchel A, Trka J, Reinhardt D, Sonneveld E, Zimmermann M, Alonzo TA, Pieters R, Meshinchi S, van den Heuvel-Eibrink MM, Zwaan CM (2013) NUP98/JARID1A is a novel recurrent abnormality in pediatric acute megakaryoblastic leukemia with a distinct HOX gene expression pattern. Leukemia 27(12):2280–2288. https://doi.org/10.1038/leu.2013.87 CrossRefPubMedGoogle Scholar
- 12.Yamato G, Yamaguchi H, Handa H, Shiba N, Kawamura M, Wakita S, Inokuchi K, Hara Y, Ohki K, Okubo J, Park MJ, Sotomatsu M, Arakawa H, Hayashi Y (2017) Clinical features and prognostic impact of PRDM16 expression in adult acute myeloid leukemia. Genes Chromosom Cancer 56(11):800–809. https://doi.org/10.1002/gcc.22483 CrossRefPubMedGoogle Scholar
- 13.Jo A, Mitani S, Shiba N, Hayashi Y, Hara Y, Takahashi H, Tsukimoto I, Tawa A, Horibe K, Tomizawa D, Taga T, Adachi S, Yoshida T, Ichikawa H (2015) High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML. Leukemia 29(5):1076–1083. https://doi.org/10.1038/leu.2015.5 CrossRefPubMedGoogle Scholar
- 14.Shiba N, Ohki K, Kobayashi T, Hara Y, Yamato G, Tanoshima R, Ichikawa H, Tomizawa D, Park MJ, Shimada A, Sotomatsu M, Arakawa H, Horibe K, Adachi S, Taga T, Tawa A, Hayashi Y (2016) High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial. Br J Haematol 172(4):581–591. https://doi.org/10.1111/bjh.13869 CrossRefPubMedGoogle Scholar
- 15.Bae E, Park CJ, Cho YU, Seo EJ, Chi HS, Jang S, Lee KH, Lee JH, Lee JH, Suh JJ, Im HJ (2013) Differential diagnosis of myelofibrosis based on WHO 2008 criteria: acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis. Int J Lab Hematol 35(6):629–636. https://doi.org/10.1111/ijlh.12101 CrossRefPubMedGoogle Scholar
- 16.Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E, Talmant P, Tichelli A, Hermouet S, Skoda RC (2007) Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 110(1):375–379CrossRefPubMedGoogle Scholar